Sugi Predict

Sugi Predict / Compounds / SCHEMBL1606188

SCHEMBL1606188

SCHEMBL1606188

Cn1c(-c2cncc(CNS(=O)(=O)CCN3C(=O)c4ccccc4C3=O)c2)c(C#N)c2ccc(Cl)cc21

nearest known ligand 0.75

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ CYP11B2 P19099 12/20 0.75
▸ CYP11B1 P15538 2/20 0.75
▸ CYP19A1 P11511 1/20 0.75
▸ MAOA P21397 1/20 0.51
▸ NTRK1 P04629 1/20 0.37
▸ PRMT5 O14744 1/20 0.37
▸ WDR77 Q9BQA1 1/20 0.37
▸ MCL1 Q07820 1/20 0.34
▸ MMP2 P08253 1/20 0.33
▸ MMP9 P14780 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ LMNA P02545 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12213217 0.88 CYP11B2 (0.56) CYP11B2CYP11B1CYP19A1MAOANTRK1
SCHEMBL1606153 0.86 CYP11B2 (0.83) CYP11B2CYP11B1CYP19A1MAOAMCL1
SCHEMBL1606722 0.86 CYP11B2 (0.83) CYP11B2CYP11B1CYP19A1MAOANTRK1
SCHEMBL1606130 0.86 CYP11B2 (1.00) CYP11B2CYP11B1CYP19A1MAOANTRK1
SCHEMBL30385209 0.86 CYP11B2 (1.00) CYP11B2CYP11B1CYP19A1MAOANTRK1
SCHEMBL1606796 0.85 CYP11B2 (0.62) CYP11B2CYP11B1CYP19A1MAOANTRK1
SCHEMBL1606784 0.83 CYP11B2 (0.84) CYP11B2CYP11B1CYP19A1MAOANTRK1
SCHEMBL1605430 0.83 CYP11B2 (0.83) CYP11B2CYP11B1CYP19A1MAOANTRK1
SCHEMBL1605655 0.81 CYP11B2 (0.80) CYP11B2CYP11B1CYP19A1MAOANTRK1
SCHEMBL1606120 0.81 CYP11B2 (0.80) CYP11B2CYP11B1CYP19A1MAOANTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9242963-B2 Organic compounds NOVARTIS AG (CH) 2016-01-26 — — US disclosed
US-20150210672-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2015-07-30 — — US disclosed
US-20140288126-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2014-09-25 — — US disclosed
US-8791141-B2 Organic compounds NOVARTIS AG (CH) 2014-07-29 — — US disclosed
US-8030334-B2 Organic compounds NOVARTIS AG (CH) 2011-10-04 — — US disclosed
US-8030334-B2 Organic compounds NOVARTIS AG (CH) 2011-10-04 — — US disclosed
EP-2307371-A2 ORGANIC COMPOUNDS Novartis AG (CH) 2011-04-13 — — EP disclosed
US-20110082129-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2011-04-07 — — US disclosed
US-20100261698-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-10-14 — — US disclosed
WO-2009156462-A2 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-12-30 — — WO disclosed
WO-2009156462-A2 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-12-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110082129-A1 ORGANIC COMPOUNDS SLCO2B1, SLCO1B1, SLCO1B3 CYP11B2 13/4885CYP11B1 14/4885CYP19A1 68/4885
US-20100261698-A1 ORGANIC COMPOUNDS SLCO2B1, SLCO1B1, SLCO1B3 CYP11B2 13/4885CYP11B1 14/4885CYP19A1 68/4885
US-20150210672-A1 ORGANIC COMPOUNDS SLCO2B1, SLCO1B1, SLCO1B3 CYP11B2 12/4885CYP11B1 15/4885CYP19A1 55/4885
US-20140288126-A1 ORGANIC COMPOUNDS SLCO2B1, SLCO1B1, SLCO1B3 CYP11B2 12/4885CYP11B1 15/4885CYP19A1 55/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.